Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Rectal Cancer

Interventions

BIOLOGICAL

CEA protein antigen plus BCG Vaccine Mix for percutaneous use

"* By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix"

Trial Locations (1)

Medicine Invention Design, Inc. (MIDI) - c/o - IORG0007849 - NPI-1023387701, Rockville

All Listed Sponsors

collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY